Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …
P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - nature.com
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka… - Leukemia, 2002 - nature.com
The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - Blood, 2004 - ashpublications.org
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid …
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in …
S Branford, Z Rudzki, A Harper, A Grigg, K Taylor… - Leukemia, 2003 - nature.com
We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid
leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to …
leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
MC Müller, N Gattermann, T Lahaye, MWN Deininger… - Leukemia, 2003 - nature.com
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
[HTML][HTML] Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the …
TP Hughes, A Hochhaus, S Branford, MC Müller… - Blood, 2008 - Elsevier
Background: An exploratory endpoint of the IRIS trial was measurement of BCR-ABL
transcripts over time and its correlation with long-term outcomes. BCR-ABL measured by …
transcripts over time and its correlation with long-term outcomes. BCR-ABL measured by …
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Purpose: To determine the clinical significance of molecular response and relapse among
patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental …
patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental …